The short version of PT-141 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-29 and is reviewed periodically as new material appears.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Primary receptor family | Melanocortin (MC1 to MC5) | Agonist activity reported at several subtypes |
| Signalling pathway | Gs, adenylyl cyclase, cyclic AMP | Canonical melanocortin signalling route |
| Backbone length | Seven amino acids | Classified as a cyclic heptapeptide |
| Ring closure | Lactam bridge | Constrains conformation and resists peptidases |
| Terminal modifications | Acetylated N-terminus, amidated C-terminus | Reduces breakdown by exopeptidases |
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
A substance is anhydrous if it contains no water. Many processes in chemistry can be impeded by the presence of water; therefore, it is important that water-free reagents and techniques are used. In practice, however, it is very difficult to achieve perfect dryness; anhydrous compounds gradually absorb water from the atmosphere so they must be stored carefully. Substances that contain water or its constituent elements are called hydrates.
== Sources == Espy, Richard (1981). The Politics of the Olympic Games: With an Epilogue, 1976–1980. University of California Press. ISBN 9780520043954. Retrieved 16 June 2013. Honey, Andrew (2000). "South Africa and the Olympic Movement" (PDF). In K.B. Wamsley; S.G. Martyn; G. H. MacDonald; R.K. Barney (eds.). Bridging Three Centuries: Intellectual Crossroads and the Modern Olympic Movement. International Symposium for Olympic Research. pp. 177–184. Retrieved 17 June 2013. Killanin, Michael Morris, Lord (1983). "V: South Africa". My Olympic Years. New York: Morrow. pp. 33–45. ISBN 978-0-688-02209-9 – via Internet Archive. Ramsamy, Sam (1991). "Apartheid and Olympism: on the Abolishment of Institutionalized Discrimination in International Sport". In Fernand Landry; Marc Landry; Magdeleine Yerlès (eds.). Sport, the Third Millennium: Proceedings of the International Symposium, Quebec City, Canada, May 21-25, 1990. Presses Université Laval. pp. 539–548. ISBN 9782763772677. Retrieved 17 June 2013.
Harper Stern (Myha'la) is a new graduate on Pierpoint’s Cross-Product Sales (CPS) desk and one of the series’ protagonists. Brilliant, ruthless, and intensely ambitious, Harper routinely lies and manipulates to get ahead. Raised in Binghamton, New York by an abusive, domineering mother alongside her twin brother John-Daniel, she never graduated from college after suffering a panic attack during her final exams and conceals this to keep her job. She moves to London to escape her past and gravitates toward Eric Tao as a mentor who validates her drive. In series 1, Harper forges college transcripts for HR, moves into Yasmin’s flat, and forms a close but fragile friendship with her. At work, she is torn between Daria, who insists on professionalism and limits, and Eric, whose aggression mirrors her own ambition; Eric admits he knows she never graduated but protects her. Harper’s early client experiences are damaging: hedge fund manager Nicole Craig sexually assaults her, and she fails to win back major client Felim Bichan, prompting Eric to trap and berate her in a conference room. Daria urges Harper to report Eric, leading to his firing. On RIF day, Harper retracts the complaint in exchange for Eric’s reinstatement and Daria’s dismissal, believing only Eric nurtures her potential. The decision isolates her and fractures her friendship with Yasmin. In series 2, Harper remains estranged from Yasmin, and has had a casual sexual relationship with Robert.
=== Antimicrobial peptides === As an arthropod, S. mutilans has no acquired immune system, which leads to the development of numerous antimicrobial peptides in its innate immune system. An antimicrobial peptide named scolopendrasin VII was discovered in S. mutilans . The peptide stimulates actin polymerization; the subsequent chemotactic migration of macrophages was also stimulated by this peptide through activating ERK (extracellular signal-regulated kinases) and protein kinase B (Akt) activity. Scolopendrasin VII was also found to stimulate chemotactic migration of FPR1-transfected RBL-2H3 cells (mast cells), and directly binds to FPR1. Scolopin 1 and 2 are antimicrobial peptides identified from the venom of S. mutilans. These peptides were identified by Sephadex gel filtration and RP-high-performance liquid chromatography. Both scolopin 1 and 2 were reported to show intense antimicrobial activities, which includes both Gram-positive and Gram-negative bacteria and fungi. It was also reported to have moderate haemolytic effects on human and rabbit red blood cells. Scolopin 1 holds the potential as an antimicrobial agent. Scolopin 2 was found able to inhibit HeLa cell proliferation in cancer research; it was also found to combine with mitochondria, which allows it to regulate apoptosis in pathways in HeLa cells. Scolopin 2 is able to significantly suppress tumour growth in mice trials without causing any side effects. It was hence considered a strong candidate for HeLa cervical cancer treatment.
Sources: en.wikipedia.org
Ehrenfreund et al. (2001) found that amino acids in CI chondrites Ivuna and Orgueil were present at much lower concentrations than in CM chondrites (~30%), and that they had a distinct composition high in β-alanine, glycine, γ-ABA, and β-ABA but low in α-aminoisobutyric acid (AIB) and isovaline. This implies that they had formed by a different synthetic pathway, and on a different parent body from the CM chondrites.
South Africa The model remained in production in South Africa, as an entry-level model until 2003. It was also sold there as the "Midge", the "Sting", and as the "Ford Tonic". A locally designed pickup based on the Familia front end, called the Rustler was also produced, and sold as the "Ford Bantam". From 1991 to 1994 Samcor also produced and sold the 323 with the 2.0 L 16-valve DOHC FE engine from the Mazda 626 and badged it "200i". Along with the 2.0 L 16-valve DOHC engine there were upgrades to the suspension and braking system. Still, the 1.6-litre GT-Ae homologation car was more powerful. This South African built model was also sold in Australia between 1989 and 1991 with minor changes, the most noticeable one being the front indicators having a clear color rather than the normal amber. These models were labeled BF as opposed to the next generation's BG.
==== Organorhodium compounds ==== Rhodium is known for its many organometallic derivatives. Rhodium(I) complexes are commonly used as catalysis, with a few being BINAP-Rh(I), DIPAMP-Rh(I), and BDPP-Rh(I). Cyclopentadienyl complexes of rhodium have been investigated as analogues of ferrocene. The parent is rhodocene, which participates in an unusual monomer-dimer equilibrium: Related cyclopentadienyl compounds include the Rh(I) and Rh(III) half-sandwich complexes (C5H5)Rh(CO)2 and Pentamethylcyclopentadienyl rhodium dichloride dimer (C5(CH3)5RhCl2)2. The latter compound is prepared by the reaction of rhodium trichloride trihydrate and pentamethylcyclopentadiene in hot methanol. A related but cationic family of hydrogenation catalysts arise from cyclooctadiene rhodium chloride dimer, Rh2Cl2(C8H12)2. The cyclooctadiene (C8H12) ligands are easily displaced, and this allows the easy introduction of chiral ligands, leading to asymmetric hydrogenations, including the Nobel Prize-winning route to the chiral drug L-DOPA. When treated with sodium borohydride and carbon monoxide, RhCl(P(C6H5)3)3 converts to the pentacoordinate complex RhH(CO)(P(C6H5)3)3, which is used commercially for the hydroformylation of alkenes. Despite its much higher cost, tris(triphenylphosphine)rhodium carbonyl hydride has displaced cheaper cobalt-based catalysts for this application.
== Decaffeinated coffee == Friedlieb Ferdinand Runge performed the first isolation of caffeine from coffee beans in 1820, after the German poet Goethe heard about his work on belladonna extract, and requested he perform an analysis on coffee beans. Though Runge was able to isolate the compound, he did not learn much about the chemistry of caffeine itself, nor did he seek to use the process commercially to produce decaffeinated coffee.
Hypothermia, especially during winter months Metabolic disruption including hypoglycemia, hyponatremia, acidosis, and hypercalcemia Respiratory compromise including hypoxemia and hypercapnia Infections including pneumonia, cellulitis, and urosepsis Congestive heart failure Cerebrovascular accidents Gastrointestinal bleeding Trauma, motor vehicle accidents, and fractures Medications including anesthetics, sedatives, tranquilizers, narcotics, amiodarone, and lithium Withdrawal of thyroid supplements, especially in relation to a hospitalization Other precipitating factors include:
Sources: en.wikipedia.org
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.
The lactam bridge locks the peptide into a defined shape and makes it harder for peptidases to cut the backbone. Terminal blocking groups add further protection at both ends. Together these features extend the molecule's persistence in circulation compared with linear peptides.
Evidence from animals favors hypothalamic melanocortin circuits, yet direct confirmation in humans is lacking. A peripheral vascular contribution has also been proposed. How receptor binding translates into a reported behavioral effect is still not mapped.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.